Dr. Bharat Jenigiri | PCI Hematology ...

Dr. Bharat Jenigiri

Claim this profile

Physicians' Clinic of Iowa PC

Studies Breast Cancer
Studies Breast cancer
15 reported clinical trials
32 drugs studied

Area of expertise

1Breast Cancer
Bharat Jenigiri has run 7 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
Stage II
Stage I
2Breast Cancer
Bharat Jenigiri has run 4 trials for Breast cancer. Some of their research focus areas include:
HER2 positive
ER negative
PR negative

Affiliated Hospitals

Image of trial facility.
Physicians' Clinic Of Iowa PC

Clinical Trials Bharat Jenigiri is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

More about Bharat Jenigiri

Clinical Trial Related11 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Bharat Jenigiri has experience with
  • Biospecimen Collection
  • Pembrolizumab
  • Lenalidomide
  • Standard Of Care Adjuvant Breast Radiation
  • Standard Of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
  • Carboplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Bharat Jenigiri specialize in?
Is Bharat Jenigiri currently recruiting for clinical trials?
Are there any treatments that Bharat Jenigiri has studied deeply?
What is the best way to schedule an appointment with Bharat Jenigiri?
What is the office address of Bharat Jenigiri?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security